Background: Cell proliferation and motility require actin reorganization, which is under control of various signalling pathways including ras-related C3 botulinum toxin substrate 1 (RAC1), p21 protein-activated kinase 1 (PAK1) and actin related protein 2 (ARP2). Tumour cell proliferation is modified by 1α,25-Dihydroxy-Vitamin D3 (1α,25(OH) 2 D 3 ), a steroid hormone predominantly known for its role in calcium and phosphorus metabolism. The present study explored whether 1α,25(OH) 2 D 3 modifies actin cytoskeleton in Ishikawa cells, a well differentiated endometrial carcinoma cell line. Methods: To this end, actin cytoskeleton was visualized by confocal microscopy. Globular over filamentous actin ratio was determined utilizing Western blotting and flow cytometry, transcript levels by qRT-PCR and protein abundance by immunoblotting. Results: A 24 hour treatment with 1α,25(OH) 2 D 3 (100 nM) significantly decreased RAC1 and PAK1 transcript levels and activity, decreased ARP2 protein levels and depolymerized actin. The effect of 1α,25(OH) 2 D 3 on actin polymerization was mimicked by pharmacological inhibition of RAC1 and PAK1. Conclusions: 1α,25(OH) 2 D 3 leads to disruption of RAC1 and PAK1 activity with subsequent actin depolymerization of endometrial carcinoma cells.
Introduction
1α,25(OH) 2 D 3 , the biologically active metabolite of Vitamin D [1] , is predominantly known for its role in mineral metabolism [2] . 1α,25(OH) 2 D 3 is, in addition, a powerful inhibitor of malignancy [3] , including endometrial cancer [4] .
Vitamin D is a fat soluble secosteroid which can be produced endogenously or obtained exogenously from dietary or supplementary sources [1] . The two major forms are vitamin D 2 (ergocalciferol; C 28 H 44 O) and D 3 (cholecalciferol; C 27 H 44 O) [1] . Vitamin D 3 is endogenously produced by UVB (ultraviolet B) radiation (wavelength 290-315 nm) converting 7-dehydrocholesterol into vitamin D 3 [2] which is transported to the liver by vitamin D-binding protein [1] . Exogenous dietary vitamin D exists as either vitamin D 2 or D 3 [5] . Both endogenous and exogenous vitamin D are converted into 25-hydroxy vitamin D (25(OH)D; C 27 H 44 O 2 ) in a reaction catalysed by 25-hydroxylase in the liver [6] . 25-hydroxy vitamin D is hydroxylated in the kidney to 1α,25-dihydroxy vitamin D 3 (1α,25(OH) 2 D 3 ; C 27 H 44 O 3 ), the biologically active form, by the enzyme 1α-hydroxylase. The renal 1α-hydroxylase is under tight regulation by parathyroid hormone (PTH), calcium and phosphate [2] . The biological actions of 1α,25(OH) 2 D 3 are achieved by binding to the vitamin D receptor (VDR) [7] .
VDR expression has been identified in a variety of tissue types, including: adipose tissue, brain, breast cancer cells, colon, liver, lung, muscle, ovary, pancreas, prostate, skin, stomach, and thyroid [8] . Expression of PTH and calcium insensitive 1α-hydroxylase has been identified in cancer and non-cancer cells, such as prostate, colon, lung, endothelial, brain, pancreatic β-cells and monocytes [1] . Current research suggests that vitamin D and its metabolites may reduce progression of many types of cancers [1] . Despite the large amount of recent research that has investigated the associations between vitamin D and cancer [9, 10] , the exact mechanism of the protective effect of vitamin D remained incompletely understood.
Effects of 1α,25(OH) 2 D 3 include reorganization of actin cytoskeleton [11] [12] [13] [14] . Apparently depending on the cell type, 1α,25(OH) 2 D 3 may either increase [11, 12, 14] or decrease [13] actin polymerisation. Early and/or late actin restructuring, following modifications of actin polymerization dynamics equilibrium, is a cellular response initiated by various signals including growth factors and cytokines [15] [16] [17] , hormones [18] [19] [20] [21] and ions [22, 23] . Alterations of actin organization, in turn, govern crucial cellular functions and outcomes such as cell volume regulation [24] , survival [25] , migration and cell motility [26, 27] , secretion [28] , cell growth and proliferation [29] as well as apoptosis [30, 31] .
Key regulators of the actin cell cytoskeleton include ras-related C3 botulinum toxin substrate 1 (RAC1) [32] , which stimulates formation of lamellipodia [33] , a prerequisite for cell motility [34] . The regulatory proteins of the actin cytoskeleton play a pivotal role for the motility of cancer cells and contribute to most steps during cancer progression [35, 36] . The ability of cancer cells to invade the surrounding tissue, crossing the endothelial barrier to metastasize at a secondary site requires a highly dynamic reorganization of the actin cytoskeleton [37] . RAC1 and other Rho GTPases were found to be overexpressed in many types of cancer [38, 39] . Down-regulation of RAC1 activity suppresses tumor growth and RAC1 was therefore identified as a potential therapeutic target for cancer cell treatment [40, 41] .
Here we report that treatment of human endometrial carcinoma cells with 1α,25(OH) 2 D 3 leads to a dramatic decrease in RAC1 activity and p21 protein-activated kinase 1 (PAK1) phosphorylation leading to actin reorganization.
Material and Methods

Cell culture
A well differentiated endometrial carcinoma cell line, Ishikawa cells (Sigma; routinely tested every 6 months for mycoplasma. The authenticity of the cells were confirmed by qPCR every 10 th passage) were cultured in DMEM/F12 without phenol red media, containing 10% fetal bovine serum (FBS), 1% antibiotic/ antimycotic solution and 0.25% L-Glutamine (Invitrogen, Karlsruhe, Germany) in a humidified atmosphere at 37°C and 5% CO 2 . Cells were treated as described with 1α,25(OH) 2 D 3 (#D1530; 100 nM; Sigma Aldrich, München, Germany), RAC1 inhibitor NSC23766 trihydrochloride (#SML0952; 100nM; Sigma Aldrich, München, Germany), or PAK1 inhibitor IPA 3 (#3622; 50 nM; Tocris bioscience, Germany) for 24 hours.
Quantitative Real-time PCR Total RNA was extracted from Ishikawa cultures using Trizol (Invitrogen) based on a phenolchloroform extraction protocol. Equal amounts of total RNA (1 μg) were reverse transcribed with the Superscript Ⅲ First-Strand synthesis system for RT-PCR (Invitrogen) primed using random hexamers, and the resulting cDNA used as template in qRT-PCR analysis. The gene-specific primer pairs were designed using the Primerblast (NCBI) software. Detection of gene expression was performed with KapaFast-SYBR Green (Peqlab, Erlangen, Germany) and quantitative RT-PCR was performed on a BioRad iCycler iQ TM Real-Time PCR Detection System (Bio-Rad Laboratories, München, Germany). The expression levels of the samples were calculated by the 2 -ΔΔCt method using L19 to normalize for variances in input cDNA and expressed as arbitrary units. All measurements were performed in duplicate. Melting curve analysis and agarose gel electrophoresis confirmed amplification specificity.
Measurement of the G/F actin ratio by Triton X-100 fractionation
To quantify actin polymerization in Ishikawa cells, cells were incubated in 100 μl of Triton X-extraction buffer containing 0.3% Triton X-100, 5 mM Tris [pH 7.4], 2 mM EGTA, 300 mM sucrose, 2 μM phalloidin, 1 mM PMSF, 10 μg/ml leupeptin, 20 μg/ml aprotinin, 1 mM sodium orthovanadate, and 50 mM NaF for 5 min on ice. The supernatant containing the soluble proteins was removed by aspiration. The Triton X-insoluble pellet was scraped from the plate directly into 100 μl of RIPA buffer. Any remaining insoluble material was removed by centrifugation. Equal volumes of each fraction were boiled in Roti-Load1 Buffer (Carl Roth, Karlsruhe, Germany) at 100°C for 10 min. Proteins were separated on 12% SDS-polyacrylamide gels and transferred to PVDF membranes (Amersham Biosciences, UK). Non-specific binding sites were blocked by 1 hour at room temperature incubation with 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween. The membranes were incubated 2 hours at room temperature with monoclonal rabbit anti-Pan-Actin (D18C11)-HRP conjugated antibody (#12748, 1:1000, Cell Signalling, Frankfurt, Germany). Antibody binding was detected with the Novex ECL Chemiluminescent Substrate Reagen Kit (Invitrogen) and densiometry was performed on scanned images using ImageJ software.
Western Blotting
Whole cell protein extracts were obtained by direct lysis in Lammelli's Buffer and boiled at 100°C for 10 min. Proteins were separated on 12% SDS-polyacrylamide gels and transferred to PVDF membranes (Amersham Biosciences, UK). Non-specific binding sites were blocked for 1 hour at room temperature with 5% non-fat dry milk in TBS-T. Membranes were incubated overnight at 4°C with anti-Rac1/Cdc42 (#4651), anti-Phospho-Rac1/Cdc42 (Ser71) (#2461), anti-ARP2 (#3128), anti-PAK1/2/3 (#2604), antiPhospho-PAK1 (Thr423)/PAK2 (Thr402) (#2601), and anti-GAPDH (#2118) (Cell Signalling, Leiden, The Netherlands). All primary antibodies were used at 1:1000, washed 3 times with TBS-T, followed by incubation with HRP-conjugated anti-rabbit secondary antibodies (#7074, 1:1000, Cell Signalling, Leiden, The Netherlands). Protein complexes were visualized with a chemiluminescent detection kit (Novex ECL) and bands were quantified using ImageJ software.
Flow Cytometry of G-and F-actin
Ishikawa cells (≈1.0×10 5 cells) were first fixed with 4% paraformaldehyde (PFA) for 15 min, then permeabilized with 1× Permeablilization buffer (eBioscience, Frankfurt, Germany) and stained with 1.0 μl of fluorescent DNaseI-Alexaflour-488 (50mg/ml) for G-actin detection and fluorescent Phalloidin-eFluor 660 (1000×) (eBioscience, Frankfurt, Germany) for F-actin detection for 15 min. The abundance of the respective labels was measured using green (FL-1) and red channel (FL-4) on FACSCalibur (BD Biosciences, Heidelberg, Germany) and analyzed using Flowjo software (Flowjo LLC, Oregon, USA). G-and F-actin geometric mean values were determined from the respective fluorescence and the ratio of G/F calculated from the geometric mean values. transcript (Fig. 4A, P=0 .032) and protein (Fig. 4B, P=0 .0001) levels, pointing to a decrease of PAK1 activity in Ishikawa cells. Pharmacological inhibition of PAK1 with IPA3 (50 nM) again mimicked the destabilizing effect of inhibited RAC1 activity on the actin network (Fig. 5) . Similar to inhibition of RAC1, inhibition of PAK1 was followed by a significant increase of soluble G-actin over F-actin in human endometrial cancer Ishikawa cells (Fig. 5A , P = 0.006; Fig. 5B , P = 0.011), an effect thus mimicking the effect of 1α,25(OH) 2 D 3 treatment (Fig. 5A , P = 0.0009; Fig. 5B , P = 0.045). In the presence of the PAK1 inhibitor the additional administration of 1α,25(OH) 2 D 3 also led to a significant further increase of the soluble G-actin over F-actin ratio in Ishikawa cells (Fig. 5B, P=0.0003 ).
Discussion
The present study describes a completely novel function of 1α,25(OH) 2 D 3 in downregulating the expression and activity of the small G-protein RAC1 and of the kinase PAK1 with subsequent actin depolymerisation.
RAC1 acting downstream of FAK/PI3K signaling [18, 42] is a key regulator of actin cytoskeleton organization [32] , and down-regulation of RAC1 expression and activity following 1α,25(OH) 2 D 3 treatment contributes to or even accounts for the observed actin reorganization. RAC1 activation is known to regulate actin polymerization interacting with the ARP2/3-mediated actin nucleation pathway rather than with the formin-mediated F-actin polymerization [43] . On the other hand, it has been reported that the long formin-mediated F-actin accounts for the cortical elasticity of cells rather than the short ARP2/3-mediated F-actin. In our study however, we observed a 1α,25(OH) 2 D 3 induced decrease of RAC1 phosphorylation and ARP2, indicating deactivation of these signaling effectors. On the other hand PAK1 has also been identified as a downstream target of the small GTPases CDC42 and RAC1 [44, 45] . Upon binding to these GTPases, PAK1 is activated thus increasing its catalytic activity [44] , resulting in peripheral actin cytoskeleton reorganization that may include cortical actin polymerization as well as formation of filopodia and membrane ruffles [46, 47] . In line with this, we observed reorganization of the actin filaments network towards substantial depolymerization of F-actin filaments. The present results are in line with previous observations in endothelial cells, whereby PAK1 phosphorylates actin, an effect resulting in actin polymerization [48] . In our results we show that treatment with 1α,25(OH) 2 D 3 reduces both RAC1 and PAK1 activity. Inhibition of these two key molecules is further expected to decrease of lamellipodia formation, which could decrease the cell area and prevent migration of cancerous cells.
In conclusion, the present study demonstrates that 1α,25(OH) 2 D 3 down-regulates expression and function of the small G-protein RAC1, ARP2 and of PAK1 with subsequent depolymerisation of the actin filaments. The reorganization of the actin filaments could decrease cancer cell survival resulting in increased cell death, as this has been reported in various tumor cells [29, 49, 50] . Moreover, given that the actin cytoskeleton significantly changes upon cellular transformation and the correlative changes in actin filament architecture in drug resistant cells, drugs that target tumor-specific actin filaments could be utilized in combination with routine therapies to enhance their effectiveness in patients. Thus, this new role of 1α,25(OH) 2 D 3 may provide new avenues to pursue the development of novel cancer therapeutics.
